Neqlofol (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate, the active ingredient in Neqlofol, is a corticosteroid/long‑acting β2‑agonist combination presented as an inhalation product for respiratory use. It is formulated to deliver anti‑inflammatory and bronchodilator effects for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults.

GNH USA supplies Neqlofol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution.

Neqlofol is indicated for the maintenance treatment of respiratory diseases affecting airway inflammation and bronchoconstriction.

Asthma: improves symptom control and reduces exacerbations Chronic obstructive pulmonary disease (COPD): enhances lung function and lowers risk of flare‑ups Bronchial hyperresponsiveness (including exercise‑induced): helps prevent airway narrowing during triggers

Neqlofol may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Oral thrush (candidiasis): fungal infection in the mouth - Hoarseness or voice change: irritation of the vocal cords - Cough: irritation from inhaled particles - Headache: mild to moderate discomfort

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing - Adrenal suppression: reduced cortisol production with long‑term use - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing

Before prescribing Neqlofol, clinicians should consider several safety measures.

Assess infection risk: avoid use during active respiratory infections Monitor growth in children: long‑term corticosteroid may affect growth velocity Ensure correct inhaler technique: proper use maximizes benefit and reduces side effects Do not discontinue abruptly: taper under medical supervision after prolonged therapy Store at room temperature: keep inhaler in original packaging, protect from moisture and heat

Neqlofol can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase systemic corticosteroid exposure - MAO inhibitors: potential cardiovascular interactions

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia - Theophylline: may raise plasma concentrations - Concurrent inhaled corticosteroids: additive systemic effects